CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Ionis Pharmaceuticals, Inc.

IONS
$5.74B
Mid Cap
NASDAQPharmaceutical PreparationsBiotechnology🇺🇸North AmericaCARLSBAD1.1K employees

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

Website

Drugs in Pipeline

44

Phase 3 Programs

11

Upcoming Catalysts

4

Next Catalyst

Apr 15, 2026

6w

Market Overview

Stock performance and key metrics

IONS News
Catalyst Timeline

5 upcoming, 0 past

Drug Pipeline

Volanesorsen

Phase 3

Familial Chylomicronemia Syndrome

Olezarsen

Phase 3

Familial Chylomicronemia Syndrome

Patent 2034

Inotersen

Phase 3

FAP

Patent 2031

ION582

Phase 3

Angelman Syndrome

ION363

Phase 3

Amyotrophic Lateral Sclerosis

zilganersen

Phase 3

Alexander Disease

Alicaforsen

Phase 3

Ulcerative Colitis

Eplontersen

Phase 3

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Donidalorsen

Phase 3

Hereditary Angioedema

Paclitaxel

Phase 3

Non-small Cell Lung Cancer

ISIS 3521

Phase 3

Lung Cancer

ISIS 757456

Phase 2

Mild Hypertension

ISIS 416858

Phase 2

End-stage Renal Disease (ESRD)

ION717

Phase 2

Prion Disease

ISIS-PTP1BRx

Phase 2

Type 2 Diabetes Mellitus

ISIS-GCGRRx - Dose Level 1

Phase 2

Type 2 Diabetes Mellitus

ION904

Phase 2

Hypertension

ISIS 104838

Phase 2

Rheumatoid Arthritis

IONIS-DMPKRx

Phase 2

Myotonic Dystrophy Type 1

ISIS-FXIRx Dose #2

Phase 2

Venous Thromboembolism

Fomivirsen sodium

Phase 2

Cytomegalovirus Retinitis

ISIS apoC-III Rx

Phase 2

Hypertriglyceridemia

ION-682884

Phase 2

Healthy Volunteers

ISIS 14803

Phase 2

Hepatitis C, Chronic

ISIS 14803, peginterferon alfa, ribavirin

Phase 2

Hepatitis C, Chronic

ISIS-GCGRRx- Dose Level 1

Phase 2

Type 2 Diabetes

ISIS-FGFR4RX

Phase 2

Obesity

ISIS CRP Rx

Phase 2

Paroxysmal Atrial Fibrillation

IONIS DGAT2Rx

Phase 2

Hepatic Steatosis

sapablursen

Phase 2

Phlebotomy Dependent Polycythemia Vera

IONIS-FB-LRx

Phase 2

Macular Degeneration

IONIS-GHR-LRx

Phase 2

Acromegaly

IONIS-STAT3Rx

Phase 2

Advanced Cancers

ION440

Phase 2

Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

ISIS-GCGRRx

Phase 2

Type 2 Diabetes

ISIS-APO(a)Rx

Phase 2

Elevated Lipoprotein(a)

ION224

Phase 2

Steatohepatitis, Nonalcoholic

ISIS 443139 10 mg

Phase 2

Huntington's Disease

IONIS-AGT-LRx

Phase 2

Chronic Heart Failure With Reduced Ejection Fraction

ISIS 113715

Phase 2

Type 2 Diabetes Mellitus

ISIS-GCCRRx

Phase 2

Type 2 Diabetes Mellitus

IONIS GHR-LRx

Phase 2

Acromegaly

GHR-LRX

Phase 2

Acromegaly

ISIS EIF4E Rx

Phase 2

Castrate-Resistant Prostate Cancer

Type 2 Diabetes Mellitus

4 drugs in this indication

Hypertension

2 drugs in this indication

Rheumatoid Arthritis

2 drugs in this indication

Familial Chylomicronemia Syndrome

2 drugs in this indication

Steatohepatitis, Nonalcoholic

1 drug in this indication

Angelman Syndrome

1 drug in this indication

Prion Disease

1 drug in this indication

Cytomegalovirus Retinitis

1 drug in this indication

Obesity

1 drug in this indication

Elevated Lipoprotein(a)

1 drug in this indication

Mild Hypertension

1 drug in this indication

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

1 drug in this indication

Acromegaly

1 drug in this indication

Huntington's Disease

1 drug in this indication

Amyotrophic Lateral Sclerosis

1 drug in this indication

Hypertriglyceridemia

1 drug in this indication

FAP

1 drug in this indication

Alexander Disease

1 drug in this indication

Healthy Volunteers

1 drug in this indication

Paroxysmal Atrial Fibrillation

1 drug in this indication

Phlebotomy Dependent Polycythemia Vera

1 drug in this indication

Ulcerative Colitis

1 drug in this indication

Castrate-Resistant Prostate Cancer

1 drug in this indication

Hepatitis C, Chronic

1 drug in this indication

Hepatic Steatosis

1 drug in this indication

Macular Degeneration

1 drug in this indication

End-stage Renal Disease (ESRD)

1 drug in this indication

Myotonic Dystrophy Type 1

1 drug in this indication

Type 2 Diabetes

1 drug in this indication

Hereditary Angioedema

1 drug in this indication

Advanced Cancers

1 drug in this indication

Non-small Cell Lung Cancer

1 drug in this indication

Chronic Heart Failure With Reduced Ejection Fraction

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply